ClinicalTrials.gg
RecruitingNCT06349473Updated Jul 2, 2026

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

A Phase 1 interventional study of SR604 and Placebo in Healthy Participants, Hemophilia A and Hemophilia B, sponsored by Equilibra Bioscience LLC. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Equilibra Bioscience LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Hemophilia A with a site in United States — 40 open to participants now, 59 under way, 17 of them phase 3. Hemophilia A · United States.

Planned enrollment
112th of 221
31 · median 32
Started
2024
with 10 others
Phase 1
28 of 299
4 open now
Primary completion
2026-09
later than 13 of 58 live
Registered
276th of 299
by date

Among the 299 studies in Hemophilia A with a site in United States, this one is the 112th largest by planned enrollment of the 221 interventional ones that give a count, is one of 11 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 13 of the 58 other live ones, and was the 276th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

40 of the 299 studies in Hemophilia A with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Hemophilia A with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).

Read the detailed description

This is a first-in-human (FIH) study to be conducted with SR604. The study will enroll healthy participants (Part A) and participants with Hemophilia A or Hemophilia B or FVII deficiency (Part B).

In Part A (single ascending dose [SAD]): Healthy participants will be randomized in a 2:1 ratio in each of the 3 to 4 (Cohort 4 is optional) sequential cohorts. All cohorts will include participants receiving active treatment with SR604 and the other participant receiving matching placebo.

In Part B (multiple ascending dose [MAD]): Participants with Hemophilia A or Hemophilia B or FVII deficiency, with or without inhibitors, will be enrolled in 4 cohorts with four dose levels and is planned to receive SR604 subcutaneously.

The overall duration of study participation will be approximately 3 months.

03

Conditions studied

  • Healthy Participants
  • Hemophilia A
  • Hemophilia B
  • Factor VII Deficiency

Keywords

  • Single ascending dose
  • Multiple ascending dose
  • Factor IX
  • Factor VIII
  • Factor VII
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part A:

  • Male participants aged 18 to 55 years, inclusive.
  • between 18 and 30 kilograms per meter square (kg/m\^2), inclusive, and weighs greater than or equal to (>=) 50 kilograms (kg), less than or equal to (\<=) 90 kg.
  • No findings on medical examination, including physical examination, 12-lead , and clinical laboratory tests.
  • Sexually active men must commit to use an effective method of while taking the study intervention and for 90 days after the dose of study intervention.

Part B:

  • Male and female participants (only female participants with congenital FVII deficiency) aged 18 to 60 years, inclusive.
  • Participants must have one of the following bleeding disorders: Severe hemophilia A (\<1% Factor VIII [FVIII]); or Severe and/or moderately severe Hemophilia B (≤ 2% Factor IX [FIX]); or Severe FVII deficiency (\<10% FVII activity). Participants with severe FVII deficiency must satisfy with either of following criteria:

    1. Participants with history of >2 bleeding events in the last 12 months require on-demand treatment with recombinant factor VIIa (rFVIIa) or plasma-derived FVII concentrates (pd-FVII) or fresh frozen plasma (FFP) for bleeding control.
    2. Participants on prophylaxis treatment with rFVIIa or pd-FVII or FFP regardless of bleeding history.
  • Participants with Hemophilia A or Hemophilia B must satisfy either of the following criteria:

    1. Participants not on prophylaxis must have a documented ABR of 6 in 12 months before screening.
    2. Participants on prophylaxis must have a documented ABR of ≥ 2 in 12 months before screening.
    3. Intolerant to current treatment regimen.
  • Medical records documenting a minimum of 2 years of bleeding event history.
  • Willing to undergo a weaning period from prior treatment or prophylaxis for Hemophilia A or Hemophilia B or FVII deficiency.
  • Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of SR604.
  • Women of must have a negative pregnancy test at the Screening Visit and agree to follow the contraception guidance during the intervention period and for at least 90 days after the last dose of SR604.

Key Exclusion Criteria:

Part A:

  • Participant has clinically significant history or evidence of cardiovascular, respiratory (including all chronic lung diseases), hepatic, renal, gastrointestinal, endocrine, neurological, immunological, bleeding, or psychiatric disorder(s).
  • Participant has a mean pulse less than (\<) 40 or greater than (>) 90 beats per minute (bpm), mean systolic blod pressure (BP) \< 90 millimeter of mercury (mmHg) or > 140 mmHg, or mean diastolic BP \< 50 mmHg or > 90 mmHg at the screening visit.
  • Participant has a mean corrected for heart rate by Fridericia's formula (QTcF) of > 450 msec at the Screening Visit.
  • Participant has had injury, trauma, and/or major surgery within 3 months before Screening, or is planned to undergo surgery during the study.
  • Participant has received vaccination within 14 days before the dose of study intervention or has a vaccination planned during the study.
  • History of one or more of the following in participants and/or family members:

    1. Factor V (FV) Leiden mutation.
    2. Activated protein C (APC) resistant.
    3. Protein C (PC) or protein S (PS) deficiency.
    4. Prothrombin 20210 mutation;
    5. Antithrombin III (ATIII) deficiency.
  • History of clinically significant intracranial hemorrhage, pneumonia, chronic liver disease, liver or kidney transplants, or malignant diseases.
  • Any medical condition (eg, diabetes, obesity.) which, in the Investigator's opinion, could compromise participant safety, interfere with study intervention metabolism, or put the study outcome at undue risk. Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or could prevent, limit or confound protocol-specified assessments.
  • Participants with a history of all types of thrombosis, including any arterial and/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and (TIA), or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded.

Part B:

  • Participants with a history of all types of thrombosis, including any arterial and/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally, participants with a history of thrombotic microangiopathy, stroke, and TIA, or abnormal findings in any prior laboratory thrombophilia evaluation will be excluded.
  • History of one or more of the following in participants and/or family members:

    1. FV Leiden mutation.
    2. APC resistant.
    3. PC or PS deficiency.
    4. Prothrombin 20210 mutation.
    5. ATIII deficiency.
  • Impaired cardiac function or clinically significant cardiac disease, including any of the following:

    1. Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment ( Grade >=2), \< 50% as determined by multiple gated acquisition or echocardiogram, or clinically significant arrhythmia.
    2. QTcF > 450 ms ECG or congenital Long QT Syndrome at the Screening Visit.
    3. Acute myocardial infarction or unstable angina pectoris \< 3 months prior to study entry.
  • Uncontrolled hypertension (systolic BP > 150 mmHg and diastolic BP > 100 mmHg), a history of hypertension crisis, or a history of hypertensive encephalopathy.
  • Participant with the following laboratory abnormalities:

    1. (ALT) or aspartate aminotransferase (AST) > 1.5 × (ULN);
    2. Total ˃3.0 × ULN and direct bilirubin ˃1.5 × ULN (unless due to Gilbert's syndrome).
  • Calculated ˂ 60 mL/min using the 2021 Chronic Kidney Disease Epidemiology Collaboration () formula at the Screening Visit.
  • Participant has positive test result for (HIV) antibody.

    1. If participants test positive for core antibody (HBcAb), additional tests including hepatitis B surface antibody, hepatitis B surface antigen (HBsAg), and hepatitis B viral deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) will be conducted to determine if there is an active infection. Participants with active infection will be excluded from the study.
    2. Participants who test positive for virus antibody will be required to have a negative result for hepatitis C viral ribonucleic acid (RNA) PCR before enrollment. Individuals with positive results for hepatitis C PCR will be excluded from the study.
  • Chronic liver disease ( class C hepatic impairment), or history of liver or kidney transplants.
  • Injury, trauma, and/or major surgery (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery), major dental procedures (extractions, etc.) within 4 weeks of the first dose of SR604 or planned surgery during the study.
  • Active infection requiring systemic antibiotic or antiviral therapy or in a sepsis condition within 14 days prior to the first dose of SR604.
  • Any medical condition (eg, diabetes, obesity) which, in the Investigator's opinion, could compromise participant safety, interfere with SR604 metabolism, or put the study outcome at undue risk.
  • Female participants who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 90 days after the last dose of SR604.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Part A: Cohort 1A (SR604 Dose 1)

    Participants will receive single subcutaneous (SC) dose of SR604 dose 1 or matching placebo to SR604 on Day 1.

    Drug: SR604 · Drug: Placebo

  • Experimental
    Part A: Cohort 2A (SR604 Dose 2)

    Participants will receive single SC dose of SR604 dose 2 or matching placebo to SR604 on Day 1.

    Drug: SR604 · Drug: Placebo

  • Experimental
    Part A: Cohort 3A (SR604 Dose 3)

    Participants will receive single SC dose of SR604 dose 3 or matching placebo to SR604 on Day 1.

    Drug: SR604 · Drug: Placebo

  • Experimental
    Part A: Cohort 4A (SR604 Dose 4)

    Participants will receive single SC dose of SR604 dose 4 or matching placebo to SR604 on Day 1.

    Drug: SR604 · Drug: Placebo

  • Experimental
    Part B: Cohort 1B (SR604 Dose 5)

    Participants with Hemophilia A or Hemophilia B or FVII deficiency will receive SR604 dose 5 as multiple SC injections every 4-weeks.

    Drug: SR604

  • Experimental
    Part B: Cohort 2B (SR604 Dose 6)

    Participants with Hemophilia A or Hemophilia B or FVII deficiency will receive SR604 dose 6 as multiple SC injections every 4-weeks.

    Drug: SR604

  • Experimental
    Part B: Cohort 3B (SR604 Dose 7)

    Participants with Hemophilia A or Hemophilia B or FVII deficiency will receive SR604 dose 7 as multiple SC injections every 4-weeks.

    Drug: SR604

  • Experimental
    Part B: Cohort 4B (SR604 Dose 8)

    Participants with Hemophilia A or Hemophilia B or FVII deficiency will receive SR604 dose 8 as multiple SC injections every 4-weeks.

    Drug: SR604

Interventions

  • DrugSR604

    SR604 will be administered as SC injection.

  • DrugPlacebo

    Placebo will be administered as single SC injection.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B or FVII deficiency will be evaluated.

    Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to 3 months

  2. Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations Markers

    Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B or FVII deficiency will be evaluated.

    Time frame: Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90

Secondary outcomes

  1. Part A: Area Under the Serum Concentration-time Curve from time Zero to the Last Quantifiable Time Point (AUC[0-t])

    The PK profile (AUC\[0-t\]) of a single ascending SC dose of SR604 in healthy participants will be assessed.

    Time frame: From Baseline (Day 1) up to Day 57

  2. Part A: Area Under the Serum Concentration-time Curve from time Zero Extrapolated to Infinity (AUC[0-inf])

    The PK profile (AUC\[0-inf\]) of a single ascending SC dose of SR604 in healthy participants will be assessed.

    Time frame: From Baseline (Day 1) up to Day 57

  3. Parts A and B: Maximum Concentration (Cmax) of SR604

    The PK profile (Cmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed.

    Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90

  4. Parts A and B: Time to Maximum Concentration (tmax) of SR604

    The PK profile (tmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed.

    Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90

  5. Parts A and B: Terminal Half-life (T1/2) of SR604

    The PK profile (T1/2) of a single ascending and multiple ascending SC dose of SR604 will be assessed.

    Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90

  6. Part A: Clearance Following Extravascular Administration (CL/F) of SR604

    The PK profile (CL/F) of a single ascending SC dose of SR604 in healthy participants will be assessed.

    Time frame: From Baseline (Day 1) up to Day 57

  7. Part A: Volume of Distribution in Terminal Phase Following Extravascular Administration (Vz/F) of SR604

    The PK profile (Vz/F) of a single ascending SC dose of SR604 in healthy participants will be assessed.

    Time frame: From Baseline (Day 1) up to Day 57

  8. Parts B: Concentration before the next dose administration (Ctrough)

    The PK profile (Ctrough) of SR604 following repeated SC injections will be assessed.

    Time frame: From Baseline (Day 1) up to Day 90

  9. Parts B: Accumulation Ratio (R) of SR604

    The PK profile (accumulation R) of SR604 following repeated SC injections will be assessed.

    Time frame: From Baseline (Day 1) up to Day 90

  10. Parts B: Number of Bleeding Events

    The preliminary clinical activity of SR604 will be assessed. Bleeding event (record traumatic or non-traumatic bleeding, number of bleeding sites \[joints or non-joints\], bleeding frequency (intervals), associated with any external triggers, level of physical activity) will be evaluated.

    Time frame: From Baseline (Day 1) up to 3 months

  11. Parts B: Annualized Bleeding Rate (ABR) in Body and Targeted Joints

    The preliminary clinical activity of SR604 will be assessed. ABR in body and targeted joined will be evaluated.

    Time frame: From Baseline (Day 1) up to 3 months

  12. Parts A and B: Number of Participants with Positive Antidrug Antibodies (ADAs)

    Number of participants with positive ADAs will be assessed.

    Time frame: Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90

07

Study locations

8 of 10 sites recruiting
  • California Clinical Trials Medical Group (CCTMG)
    Glendale, California 91206, United States
    Completed

    Not enrolling at this site.

  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
  • LA Center for Bleeding and Clotting Disorders - Metairie
    Metairie, Louisiana 70001, United States
    Recruiting
  • University of Michigan Hospitals - Michigan Medicine
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27834, United States
    Not yet recruiting
  • Penn State Milton S Hershey Medical Center Pediatrics
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • McMaster University Medical Centre, Hamilton Health Sciences
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2026, 28 months after the start.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 28 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 5, 2024
StartActual
May 10, 2024
Primary completionEst.
Sep 28, 2026
CompletionEst.
Sep 28, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06349473
Lead sponsor
Equilibra Bioscience LLC
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
May 10, 2024
Primary completion
Sep 28, 2026 (estimated)
Completion
Sep 28, 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Clinical Trials
Contact
inf@equilibrabioscience.com
925-490-0278

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SR604

Start the discussion